生物医学转化 (Dec 2021)
Comparative study on different clinical features and BRAFV600E mutation rate of papillary thyroid carcinoma
Abstract
Objective To investigate the correlation between BRAFV600E and different clinical features of Papillary Thyroid Carcinoma (PTC). Methods The clinical and pathological data of 164 patients diagnosed with PTC between December 2016 to December 2019 in Baoding First Central Hospital were selected, detecting the BRAFV600E gene mutation in patients and analyzing the correlation between BRAFV600E mutation rate and different clinicopathological characteristics in order to investigate the effect of BRAFV600E mutation on clinicopathological characteristics and prognosis of PTC patients. Results A total of 164 PTC patients were included, 52 (31.7%) patients had papillary thyroid carcinoma combined with Hashimoto's thyroiditis, 132 (80.5%) patients developed cervical lymph node metastasis, 48 (29.3%) patients were≥55 years old, and 108 (65.9%) patients were detected BRAFV600E mutation. Hashimoto's thyroiditis was associated with the age, lesion location, maximum tumor diameter and nodular calcification in PTC patients (P<0.05) Lymph node metastasis was associated with the age and BRAFV600E gene mutation of PTC patients (P<0.05). Age (<55 years old, ≥55 years old) was associated with lesion type, maximum tumor diameter, lymph node metastasis and presence of Hashimoto's thyroiditis in PTC patients (P<0.05). Conclusion BRAFV600E is an important driver gene during carcinogenesis of PTC patients and has a certain proportion of mutation rate in PTC patients. The prognosis of Hashimoto's thyroiditis combined with PTC is better regardless of the presence or absence of BRAFV600E mutation premise. When the BRAFV600E mutation is present in PTC lymph node metastasis is more likely to occur and clinical decision-making is more cautious in lymphadenectomy. The BRAFV600E gene in combination with the cut-off of 55 years old doesn't give significance for PTC diagnosis and prognosis.
Keywords
